Bath & Body Works (NYSE:BBWI - Get Free Report) had its price objective reduced by equities research analysts at Telsey Advisory Group from $25.00 to $22.00 in a research note issued to investors on Thursday. The firm presently has a "market perform" rating on the stock. Telsey Advisory Group's target price would suggest a potential upside of 12.45% from the company's current price.
A number of other brokerages have also recently commented on BBWI. Piper Sandler assumed coverage on shares of Bath & Body Works in a research report on Friday, May 15th. They issued a "neutral" rating and a $20.00 target price for the company. UBS Group reduced their target price on shares of Bath & Body Works from $22.00 to $19.00 and set a "neutral" rating for the company in a research report on Wednesday, May 20th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Bath & Body Works from $21.00 to $22.00 and gave the company a "hold" rating in a research report on Tuesday, March 3rd. Citigroup cut shares of Bath & Body Works from a "buy" rating to a "neutral" rating and raised their price objective for the stock from $21.00 to $25.00 in a research report on Tuesday, February 17th. Finally, Raymond James Financial restated a "market perform" rating on shares of Bath & Body Works in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to MarketBeat, Bath & Body Works has an average rating of "Hold" and an average target price of $21.57.
View Our Latest Research Report on Bath & Body Works
Bath & Body Works Stock Up 10.3%
Shares of NYSE BBWI opened at $19.56 on Thursday. The firm has a 50-day simple moving average of $18.65 and a 200-day simple moving average of $20.24. The stock has a market capitalization of $3.94 billion, a price-to-earnings ratio of 6.21, a price-to-earnings-growth ratio of 1.76 and a beta of 1.43. Bath & Body Works has a 52 week low of $14.27 and a 52 week high of $33.96.
Bath & Body Works (NYSE:BBWI - Get Free Report) last issued its earnings results on Wednesday, May 27th. The company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.03. The business had revenue of $1.38 billion during the quarter, compared to analysts' expectations of $1.36 billion. Bath & Body Works had a net margin of 8.90% and a negative return on equity of 45.60%. The company's quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.49 earnings per share. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. As a group, equities research analysts expect that Bath & Body Works will post 2.61 EPS for the current year.
Institutional Investors Weigh In On Bath & Body Works
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its position in shares of Bath & Body Works by 217.7% during the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock valued at $35,000 after acquiring an additional 801 shares during the last quarter. Danske Bank A S purchased a new position in shares of Bath & Body Works in the third quarter valued at approximately $39,000. Global Retirement Partners LLC purchased a new position in shares of Bath & Body Works in the fourth quarter valued at approximately $31,000. Activest Wealth Management purchased a new position in shares of Bath & Body Works in the fourth quarter valued at approximately $32,000. Finally, Advisory Services Network LLC purchased a new position in shares of Bath & Body Works in the third quarter valued at approximately $48,000. 95.14% of the stock is currently owned by institutional investors and hedge funds.
Key Bath & Body Works News
Here are the key news stories impacting Bath & Body Works this week:
About Bath & Body Works
(
Get Free Report)
Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.
Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.